Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma

Sundar Jagannath, Leonard T. Heffner, Sikander Ailawadhi, Nikhil C. Munshi, Todd M. Zimmerman, Jacalyn Rosenblatt, Sagar Lonial, Asher A Chanan Khan, Markus Ruehle, Faiza Rharbaoui, Thomas Haeder, Andrea Wartenberg-Demand, Kenneth C. Anderson

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Indatuximab ravtansine (BT062) was investigated in patients with relapsed and/or refractory multiple myeloma. Indatuximab ravtansine was generally well-tolerated and showed anti-tumor activity. Based on the study results, a multi-dose schedule was selected for further clinical investigation in combination regimens.

Original languageEnglish (US)
JournalClinical Lymphoma, Myeloma and Leukemia
DOIs
StatePublished - Jan 1 2019

Fingerprint

Multiple Myeloma
Appointments and Schedules
Neoplasms

Keywords

  • Antibody-drug conjugate
  • CD138
  • Monoclonal antibody
  • Multiple-dose
  • Syndecan-1

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma. / Jagannath, Sundar; Heffner, Leonard T.; Ailawadhi, Sikander; Munshi, Nikhil C.; Zimmerman, Todd M.; Rosenblatt, Jacalyn; Lonial, Sagar; Chanan Khan, Asher A; Ruehle, Markus; Rharbaoui, Faiza; Haeder, Thomas; Wartenberg-Demand, Andrea; Anderson, Kenneth C.

In: Clinical Lymphoma, Myeloma and Leukemia, 01.01.2019.

Research output: Contribution to journalArticle

Jagannath, S, Heffner, LT, Ailawadhi, S, Munshi, NC, Zimmerman, TM, Rosenblatt, J, Lonial, S, Chanan Khan, AA, Ruehle, M, Rharbaoui, F, Haeder, T, Wartenberg-Demand, A & Anderson, KC 2019, 'Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma', Clinical Lymphoma, Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2019.02.006
Jagannath, Sundar ; Heffner, Leonard T. ; Ailawadhi, Sikander ; Munshi, Nikhil C. ; Zimmerman, Todd M. ; Rosenblatt, Jacalyn ; Lonial, Sagar ; Chanan Khan, Asher A ; Ruehle, Markus ; Rharbaoui, Faiza ; Haeder, Thomas ; Wartenberg-Demand, Andrea ; Anderson, Kenneth C. / Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma. In: Clinical Lymphoma, Myeloma and Leukemia. 2019.
@article{a0650d1911334a49bd8a6db948afbbc5,
title = "Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma",
abstract = "Indatuximab ravtansine (BT062) was investigated in patients with relapsed and/or refractory multiple myeloma. Indatuximab ravtansine was generally well-tolerated and showed anti-tumor activity. Based on the study results, a multi-dose schedule was selected for further clinical investigation in combination regimens.",
keywords = "Antibody-drug conjugate, CD138, Monoclonal antibody, Multiple-dose, Syndecan-1",
author = "Sundar Jagannath and Heffner, {Leonard T.} and Sikander Ailawadhi and Munshi, {Nikhil C.} and Zimmerman, {Todd M.} and Jacalyn Rosenblatt and Sagar Lonial and {Chanan Khan}, {Asher A} and Markus Ruehle and Faiza Rharbaoui and Thomas Haeder and Andrea Wartenberg-Demand and Anderson, {Kenneth C.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.clml.2019.02.006",
language = "English (US)",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2669",
publisher = "Cancer Media Group",

}

TY - JOUR

T1 - Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma

AU - Jagannath, Sundar

AU - Heffner, Leonard T.

AU - Ailawadhi, Sikander

AU - Munshi, Nikhil C.

AU - Zimmerman, Todd M.

AU - Rosenblatt, Jacalyn

AU - Lonial, Sagar

AU - Chanan Khan, Asher A

AU - Ruehle, Markus

AU - Rharbaoui, Faiza

AU - Haeder, Thomas

AU - Wartenberg-Demand, Andrea

AU - Anderson, Kenneth C.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Indatuximab ravtansine (BT062) was investigated in patients with relapsed and/or refractory multiple myeloma. Indatuximab ravtansine was generally well-tolerated and showed anti-tumor activity. Based on the study results, a multi-dose schedule was selected for further clinical investigation in combination regimens.

AB - Indatuximab ravtansine (BT062) was investigated in patients with relapsed and/or refractory multiple myeloma. Indatuximab ravtansine was generally well-tolerated and showed anti-tumor activity. Based on the study results, a multi-dose schedule was selected for further clinical investigation in combination regimens.

KW - Antibody-drug conjugate

KW - CD138

KW - Monoclonal antibody

KW - Multiple-dose

KW - Syndecan-1

UR - http://www.scopus.com/inward/record.url?scp=85063451981&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063451981&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2019.02.006

DO - 10.1016/j.clml.2019.02.006

M3 - Article

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2669

ER -